William Blair Maintains Outperform on Karuna Therapeuticsto Outperform
Portfolio Pulse from Benzinga Newsdesk
William Blair analyst Myles Minter maintains his 'Outperform' rating on Karuna Therapeutics (NASDAQ:KRTX).
July 13, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karuna Therapeutics' stock rating has been maintained at 'Outperform' by William Blair analyst Myles Minter.
The 'Outperform' rating indicates that the analyst believes the company's stock will do better than the market average. This could lead to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100